T0	KEYPHRASE-NOTYPES 4 18	manifestations
T1	KEYPHRASE-NOTYPES 22 34	Lyme disease
T2	KEYPHRASE-NOTYPES 62 73	antibiotics
T3	KEYPHRASE-NOTYPES 75 82	therapy
T4	KEYPHRASE-NOTYPES 95 105	resolution
T5	KEYPHRASE-NOTYPES 131 142	development
T6	KEYPHRASE-NOTYPES 146 174	disease manifestations
T7	KEYPHRASE-NOTYPES 180 187	classes
T8	KEYPHRASE-NOTYPES 191 202	antibiotics
T9	KEYPHRASE-NOTYPES 232 245	effectiveness
T10	KEYPHRASE-NOTYPES 278 287	b-lactams
T11	KEYPHRASE-NOTYPES 292 317	particular cephalosporins
T12	KEYPHRASE-NOTYPES 319 332	tetracyclines
T13	KEYPHRASE-NOTYPES 350 356	extent
T14	KEYPHRASE-NOTYPES 358 368	macrolides
T15	KEYPHRASE-NOTYPES 379 397	treatment approach
T16	KEYPHRASE-NOTYPES 417 425	duration
T17	KEYPHRASE-NOTYPES 429 436	therapy
T18	KEYPHRASE-NOTYPES 443 449	matter
T19	KEYPHRASE-NOTYPES 453 467	ongoing debate
T20	KEYPHRASE-NOTYPES 502 510	patients
T21	KEYPHRASE-NOTYPES 539 546	species
T22	KEYPHRASE-NOTYPES 550 557	strains
T23	KEYPHRASE-NOTYPES 599 610	antibiotics
T24	KEYPHRASE-NOTYPES 637 646	treatment
T25	KEYPHRASE-NOTYPES 650 662	Lyme disease
T26	KEYPHRASE-NOTYPES 677 695	available evidence
T27	KEYPHRASE-NOTYPES 712 729	controlled trials
T28	KEYPHRASE-NOTYPES 731 735	RCTs
T29	KEYPHRASE-NOTYPES 738 763	treatment recommendations
T30	KEYPHRASE-NOTYPES 791 818	Infectious Diseases Society
T31	KEYPHRASE-NOTYPES 822 829	America
T32	KEYPHRASE-NOTYPES 831 835	IDSA
T33	KEYPHRASE-NOTYPES 848 864	American Academy
T34	KEYPHRASE-NOTYPES 868 878	Pediatrics
T35	KEYPHRASE-NOTYPES 895 902	variety
T36	KEYPHRASE-NOTYPES 919 945	supranational associations
T37	KEYPHRASE-NOTYPES 949 955	Europe
T38	KEYPHRASE-NOTYPES 967 970	www
T39	KEYPHRASE-NOTYPES 971 977	eucalb
T40	KEYPHRASE-NOTYPES 978 981	com
T41	KEYPHRASE-NOTYPES 991 1001	comparison
T42	KEYPHRASE-NOTYPES 1014 1024	guidelines
T43	KEYPHRASE-NOTYPES 1042 1046	IDSA
T44	KEYPHRASE-NOTYPES 1055 1061	EUCALB
T45	KEYPHRASE-NOTYPES 1065 1070	Table
T46	KEYPHRASE-NOTYPES 1090 1100	approaches
T47	KEYPHRASE-NOTYPES 1104 1111	therapy
T48	KEYPHRASE-NOTYPES 1140 1145	sides
T49	KEYPHRASE-NOTYPES 1153 1161	Atlantic
T50	KEYPHRASE-NOTYPES 1182 1199	minor differences
T51	KEYPHRASE-NOTYPES 1219 1225	dosage
T52	KEYPHRASE-NOTYPES 1230 1248	treatment duration
T53	KEYPHRASE-NOTYPES 1264 1282	International Lyme
T54	KEYPHRASE-NOTYPES 1298 1314	Diseases Society
T55	KEYPHRASE-NOTYPES 1334 1344	guidelines
T56	KEYPHRASE-NOTYPES 1353 1363	management
T57	KEYPHRASE-NOTYPES 1367 1379	Lyme disease
T58	KEYPHRASE-NOTYPES 1429 1446	treatment courses
T59	KEYPHRASE-NOTYPES 1451 1459	patients
T60	KEYPHRASE-NOTYPES 1465 1484	persistent symptoms
T61	KEYPHRASE-NOTYPES 1488 1506	refractory disease
T62	KEYPHRASE-NOTYPES 1524 1535	terminology
T63	KEYPHRASE-NOTYPES 1569 1577	evidence
T64	KEYPHRASE-NOTYPES 1610 1617	studies
T65	KEYPHRASE-NOTYPES 1639 1647	approach
T66	KEYPHRASE-NOTYPES 1672 1696	available evidence
T67	KEYPHRASE-NOTYPES 1702 1709	results
T68	KEYPHRASE-NOTYPES 1713 1725	several RCTs
T69	KEYPHRASE-NOTYPES 1732 1757	large retrospective study
T70	KEYPHRASE-NOTYPES 1774 1781	benefit
T71	KEYPHRASE-NOTYPES 1799 1807	duration
T72	KEYPHRASE-NOTYPES 1811 1820	treatment
T73	KEYPHRASE-NOTYPES 1826 1837	doxycycline
T74	KEYPHRASE-NOTYPES 1846 1850	days
T75	KEYPHRASE-NOTYPES 1863 1867	days
T76	KEYPHRASE-NOTYPES 1871 1879	patients
T77	KEYPHRASE-NOTYPES 1885 1887	EM
T78	KEYPHRASE-NOTYPES 1924 1928	data
T79	KEYPHRASE-NOTYPES 1939 1957	similar conclusion
T80	KEYPHRASE-NOTYPES 1962 1973	amoxicillin
T81	KEYPHRASE-NOTYPES 1992 2008	double-blind RCT
T82	KEYPHRASE-NOTYPES 2010 2019	treatment
T83	KEYPHRASE-NOTYPES 2023 2031	patients
T84	KEYPHRASE-NOTYPES 2050 2066	Lyme borreliosis
T85	KEYPHRASE-NOTYPES 2074 2087	3-week course
T86	KEYPHRASE-NOTYPES 2096 2107	ceftriaxone
T87	KEYPHRASE-NOTYPES 2124 2128	days
T88	KEYPHRASE-NOTYPES 2132 2143	amoxicillin
T89	KEYPHRASE-NOTYPES 2164 2171	outcome
T90	KEYPHRASE-NOTYPES 2186 2199	3-week course
T91	KEYPHRASE-NOTYPES 2203 2214	ceftriaxone
T92	KEYPHRASE-NOTYPES 2234 2242	findings
T93	KEYPHRASE-NOTYPES 2268 2276	patients
T94	KEYPHRASE-NOTYPES 2309 2327	aggressive therapy
T95	KEYPHRASE-NOTYPES 2337 2355	risk-benefit ratio
T96	KEYPHRASE-NOTYPES 2393 2411	individual patient
